Decorporation therapy with DTPA (diethylene triamine pentaacetic acid) is recommended as a standard procedure after accidental intake of transuranics such as plutonium/americium (Pu/Am). DTPA is able to chelate the incorporated Pu/Am and eliminate them rapidly from the body, mainly by enhancing their urinary excretion rate. In general Ca/Zn-DTPA is administered following empirical protocols. Since the chelation process perturbs the regular biokinetics of Pu/Am, standard biokinetic models are inadequate for interpreting monitoring data and estimating dose to the patient. Moreover, optimization of the treatment strategy and prospective assessments of the therapy success in terms of averted dose cannot be evaluated by using the current models. In the recent years a European collaboration within the frame of EURADOS (European Radiation Dosimetry Network) has been initiated to develop a compartmental model approach to this issue. The basic idea of the adopted approach is to consider the biokinetics of Pu/Am and of the injected DTPA separately and to couple them by a suitable mathematical description of the chelation mechanism as a second-order process [1, 2]. Except the proposal presented by Konzen and Brey [3], which is based on the EURADOS approach, all other attempts existing in the literature [4-9] are empirical and developed mainly for the interpretation of one or a limited number of specific incorporation cases. In this work the available experimental data from controlled animal studies with Am recently published by Grémy et al. [10] was used to define the biological sites of chelation and the chelation rate constants. Rats were given DTPA either prior to or after Am intravenous injection. In these studies all boundary conditions are precisely known, differently from the case of accidental intakes in humans. The chelation rate constants and the identification of the chelation sites are thus the only unknown variables of the system. In a first step, chelation was assumed to occur only in extracellular fluids, with two different rate constants for chelation in blood and chelation in other fluids (lymph, interstitial fluids). Model predictions reproduce the accumulation of activity in urine until time of sample collection, corresponding to a 24h period in the studies of Grémy et al. Predictions were compared with the experimental 24h urinary excretions (Fig. 1). While there is a good agreement between prediction and data when DTPA has been administered shortly after contamination (top left panel), the agreement for the other experiments is less satisfactory. Moreover, increased faecal excretion and decorporation from liver and
[1]
A. Perkins,et al.
Internal Radiation Dosimetry
,
2019,
Problems and Solutions in Medical Physics.
[2]
L. Miccoli,et al.
Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action
,
2016,
Radiation Research.
[3]
R. Brey,et al.
Development of the Plutonium-DTPA Biokinetic Model
,
2015,
Health physics.
[4]
C. Hoeschen,et al.
Developing a physiologically based approach for modeling plutonium decorporation therapy with DTPA
,
2014,
International journal of radiation biology.
[5]
J. Mcdonald.
Too much of a good thing?
,
2009,
Radiation protection dosimetry.
[6]
B. Breustedt,et al.
Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
,
2009,
Radiation protection dosimetry.
[7]
P. Fritsch,et al.
Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: biokinetics and dosimetric approaches.
,
2007,
Radiation protection dosimetry.
[8]
E. H. Carbaugh,et al.
Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
,
2007,
Radiation protection dosimetry.
[9]
Smith Ja,et al.
A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy.
,
1978
.
[10]
K. Heid,et al.
Interpretation of human urinary excretion of plutonium for cases treated with DTPA.
,
1972,
Health physics.
[11]
E. Smith.
Internal radiation dosimetry.
,
1967,
Environmental health series. RH, Radiological health.